ORLANDO — In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic, talks about findings from the phase 2 LUNA trial.
Stewart told Healio that Ixo-vec (ixoberogene soroparvovec, Adverum Biotechnologies) in neovascular age-related macular degeneration “showed excellent safety signals” throughout the 4-year study period.
“That really, to me, is the No. 1 concern with gene therapy, even more so than the efficacy. Is it going to be safe?” he said.
“Inflammation, [retinal pigment epithelium] damage, anything